LHR
NMRA icon

Lunate Holding RSC’s Neumora Therapeutics NMRA Stock Holding History

Lunate Holding RSC’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$22.5M Buy
+2,124,143
New +$25.5M 10.67% 4

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Lunate Holding RSC's NMRA Position: Q4 2024 in Review

Lunate Holding RSC opened a new position in Neumora Therapeutics (NMRA) in Q4 2024: 2,124,143 shares worth $22.5M. The stake represents 10.67% of the portfolio and ranks #4 among its holdings.

134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Lunate Holding RSC held 2,124,143 shares of Neumora Therapeutics worth $22.5M as of Q4 2024.
  • Neumora Therapeutics was a new Lunate Holding RSC position in Q4 2024.
  • Neumora Therapeutics made up 10.67% of Lunate Holding RSC's portfolio in Q4 2024, its #4 holding.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Lunate Holding RSC's 13F filing for Q4 2024, filed 14 Feb 2025.